Penumbra, Inc. $PEN Position Boosted by Machina Capital S.A.S.

Machina Capital S.A.S. increased its position in Penumbra, Inc. (NYSE:PEN) by 17.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,263 shares of the company’s stock after purchasing an additional 1,840 shares during the quarter. Machina Capital S.A.S.’s holdings in Penumbra were worth $3,904,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PEN. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Penumbra during the 2nd quarter valued at about $25,000. Keating Financial Advisory Services Inc. bought a new position in shares of Penumbra in the 2nd quarter valued at about $31,000. MassMutual Private Wealth & Trust FSB grew its position in shares of Penumbra by 48.7% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 116 shares of the company’s stock worth $37,000 after buying an additional 38 shares during the period. CoreCap Advisors LLC grew its position in shares of Penumbra by 1,066.7% during the 3rd quarter. CoreCap Advisors LLC now owns 140 shares of the company’s stock worth $45,000 after buying an additional 128 shares during the period. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Penumbra during the 2nd quarter worth approximately $51,000. 88.88% of the stock is owned by institutional investors.

Penumbra Stock Up 0.1%

Shares of Penumbra stock opened at $321.78 on Thursday. The company has a quick ratio of 3.92, a current ratio of 5.89 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a 12 month low of $274.20 and a 12 month high of $362.41. The business has a fifty day simple moving average of $320.23 and a 200 day simple moving average of $326.47. The stock has a market cap of $12.68 billion, a PE ratio of 81.38 and a beta of 0.71.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Thursday, October 29th. The company reported $1.07 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.13). Penumbra had a net margin of 10.06% and a return on equity of 10.39%. The company had revenue of $410.15 million during the quarter, compared to the consensus estimate of $401.41 million. During the same quarter in the prior year, the company posted $0.97 EPS. The company’s revenue for the quarter was up 15.6% compared to the same quarter last year. Research analysts predict that Penumbra, Inc. will post 4.96 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PEN shares. Weiss Ratings raised shares of Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, October 30th. Zacks Research raised shares of Penumbra from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $367.07.

About Penumbra

Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.